Literature DB >> 2752538

Glycolysis and glutaminolysis in perifused Ehrlich ascites tumour cells.

J A Segura1, M A Medina, F J Alonso, F Sanchez-Jimenez, I Núñez de Castro.   

Abstract

A perifusion system was designed in order to study glucose and glutamine metabolism by freshly harvested Ehrlich ascites tumour cells in steady state conditions. Cells were perifused in the presence of 5 mM glucose, 0.5 mM glutamine or 5 mM glucose and 0.5 mM glutamine. The results in steady state reveal that both substrates glucose and glutamine are continuously wasted by tumour cells, excreting two moles of lactate per mol of glucose and one mol of glutamate and ammonia per mol of glutamine consumed into the medium. Glutamine consumption in the presence of glucose was higher than with glutamine alone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2752538     DOI: 10.1002/cbf.290070103

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  4 in total

Review 1.  Relevance of glutamine metabolism to tumor cell growth.

Authors:  M A Medina; F Sánchez-Jiménez; J Márquez; A Rodríguez Quesada; I Núñez de Castro
Journal:  Mol Cell Biochem       Date:  1992-07-06       Impact factor: 3.396

2.  Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells.

Authors:  Meng Meng; Shuyang Chen; Taotao Lao; Dongming Liang; Nianli Sang
Journal:  Cell Cycle       Date:  2010-10-25       Impact factor: 4.534

3.  Simultaneous fluorometric determination of intracellular polyamines separated by reversed-phase high-performance liquid chromatography.

Authors:  J M Matés; J Márquez; M García-Caballero; I Núñez de Castro; F Sánchez-Jiménez
Journal:  Agents Actions       Date:  1992-05

4.  Physiological Role of Glutamate Dehydrogenase in Cancer Cells.

Authors:  Rafael Moreno-Sánchez; Álvaro Marín-Hernández; Juan C Gallardo-Pérez; Silvia C Pacheco-Velázquez; Diana X Robledo-Cadena; Joaquín Alberto Padilla-Flores; Emma Saavedra; Sara Rodríguez-Enríquez
Journal:  Front Oncol       Date:  2020-04-09       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.